Skip to main content
Equibles
GCAND logo

GCAND · Trafalgar International, Inc.

Track GCAND — free

Use GCAND with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research GCAND.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.40 At close · Oct 9
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“We have therefore concluded there is substantial doubt about our ability to continue as a going concern through June 2027.”
View the 10-Q filed Aug 14, 2026
Market Cap
$278,426
Shares
198,876
Volume · Oct 9 266 Avg daily vol (10 sessions) 1376

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.40 Open$1.40 Day$1.40–1.40 52W close$0.26–2.35 Avg vol 30d2K Short int99 · 0.0% float · 1.0d Short vol94% DataJan 2020–Oct 2026 Filing10-Q · Aug 14

Up next

Latest filing: 10-Q
filed Aug 14, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
$879,660
Trailing 12 months
Revenue growth YoY
-73.7%
Year over year
Operating margin
-2,716.9%
Trailing 12 months
P / E (TTM)
0.3
Trailing earnings · reciprocal yield 371.4%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$111
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+8.2%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
—
Latest settlement
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Neutral Momentum Very Strong Sentiment Neutral Fundamentals Poor Quant / Vol Very High
Market backdrop VIX 14.8 · calm Equity put/call 0.56
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +12%
above
Price vs 50-day avg +0%
above
RSI (14) 47
neutral
MACD trend Negative
52-week position 55%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +22%
trailing
6-month return +437%
trailing
YTD return +273%
this year
Relative strength +428%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow Flat
No 13F holder data
Insider flow Flat
No net insider activity over 90 days
Short interest Flat
0.05% of float · ▬ 0.0% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
No 13F holder history
Fundamentals
Poor
Revenue growth −93%
Y/Y
Gross margin -0%
contracting
Quant / Vol
risk profile
Very High
Volatility 646%
annualized · 1-yr
Max drawdown −98%
past year
ATR 17.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+12% Bullish
Price vs 50-day avg
+0% Bullish
RSI (14)
47 Neutral
MACD trend
Negative Bearish
52-week position
55% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
No clear signal
Trend (MA cross) No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow Flat
No 13F holder data
Insider flow Flat
No net insider activity over 90 days
Short interest Flat
0.05% of float · ▬ 0.0% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
No 13F holder history
Price context
position in its 52-week range
Range low $0 Now $1 · 55% Range high $2
vs 200-day avg +12% vs 50-day avg +0%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
GCAND
Trafalgar International, Inc.
this stock
$278,426 — -92.5% — 0.3%
TAK
Takeda Pharmaceutical Co Ltd
 $59.83B +20.1% — — 0.1%
TEVA
Teva Pharmaceutical Industries Ltd
 $47.89B +31.7% +4.3% 67.4 2.6%
GALDY
Galderma Group AG/ADR
 $46.39B -4.0% — — 0.0%
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
 $41.48B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Short & Settlement
Short Interest
Shares short
99
Days to cover
1.0d
Change
0 sh
View
Short Volume
Short vol %
94%
As of
Oct 7, 2026
Short Total
View
Off-Exchange
Off-exchange %
100.0%
Week of
Nov 17, 2025
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$12.6K
Net income (FY)
$-331.6K
EPS diluted
$0.00
View
Filings
SEC Filings
Latest
8-K
Filed
Sep 21, 2026
This year
6
View

Performance

5D 20D 120D MTD YTD
GCAND -13.6% +21.7% +437.4% -12.5% +273.3%
SPY +1.2% +1.9% +9.9% +2.1% +14.2%
vs SPY -14.7% +19.8% +427.6% -14.6% +259.2%
Key facts CIK 1695473 Visit website Investor relations